Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Non-Controlling Interests: 2022-2024

Historic Income from Non-Controlling Interests for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $88.4 million.

  • Day One Biopharmaceuticals' Income from Non-Controlling Interests rose 154.56% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.3 million, marking a year-over-year increase of 73.74%. This contributed to the annual value of $88.4 million for FY2024, which is 53.23% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Income from Non-Controlling Interests of $88.4 million as of FY2024, which was down 53.23% from $188.9 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Income from Non-Controlling Interests peaked at $188.9 million during FY2023, and registered a low of $88.4 million during FY2024.
  • In the last 3 years, Day One Biopharmaceuticals' Income from Non-Controlling Interests had a median value of $142.2 million in 2022 and averaged $139.8 million.
  • Its Income from Non-Controlling Interests has fluctuated over the past 5 years, first spiked by 32.87% in 2023, then tumbled by 53.23% in 2024.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Income from Non-Controlling Interests stood at $142.2 million in 2022, then skyrocketed by 32.87% to $188.9 million in 2023, then slumped by 53.23% to $88.4 million in 2024.